Home>Topics>Stocks>C.R. Bard

C.R. Bard

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
  1. Medtronic: Benefits Of Covidien Acquisition Not Enough To Make It A Buy

    Headlines

    Wed, 10 Sep 2014

    By Dividends4Life : Linked here is a detailed quantitative analysis of Medtronic Inc. (NYSE: MDT ). Below are some highlights from the above linked analysis: Company Description: Medtronic Inc. is a global medical device manufacturer has leadership positions in the pacemaker, defibrillator, ...

  2. CR Bard Bolsters Narrow Moat With Technology That Appeals to Hospitals Seeking Efficiencies

    Commentary

    Mon, 25 Aug 2014

    We have long appreciated CR Bard 's narrow economic moat and have recently taken another look at the firm's product portfolio and general approach to navigating

  3. Fitch Revises BCR's Outlook to Negative; Affirms at 'BBB+'

    Headlines

    Tue, 12 Aug 2014

    based Banca Comerciala Romana S.A.'s ( BCR ) Long-term foreign and local currency ..... at 'F2' and Support Rating at '2'. BCR 's Viability Rating (VR) was not affected ..... RATING DRIVERS: IDRs AND SUPPORT RATING BCR 's IDRs and Support Ra

  4. New Morningstar Analyst Report for CR Bard Inc

    Stock Reports

    Tue, 29 Jul 2014

    substantial market share decline for Bard. C . R . Bard 's line of infection-control products ..... when capital spending is low. We rate C . R . Bard 's stewardship as Standard. Chairman ..... lower executive compensation rates than C . R . Bard . We also would like to see more disclosure

  5. Boston Scientific Exceeds Our Expectations in the Second Quarter

    Commentary

    Thu, 24 Jul 2014

    in constant currency, propelled by urology and women's products. Moreover, the electrophysiology business purchased from CR Bard provided a boost by rounding out Boston's portfolio with complementary products. Boston held gross margin steady at 70

  6. New Morningstar Analyst Report for Endo International PLC

    Stock Reports

    Thu, 19 Jun 2014

    facing lawsuits related to patient injuries caused by its vaginal mesh products. The issue is not unique to Endo--competitors CR Bard , Boston Scientific, Johnson & Johnson, and others are facing litigation for similar products--but it could face a significant

  7. CR Bard Sees Boost in First Quarter Thanks to Gore Royalties and Acquisitions

    Commentary

    Tue, 22 Apr 2014

    CR Bard reported first-quarter results that slightly exceeded our expectations, thanks to acquisitions made last year as well as royalty

  8. CR Bard Underlying Business Remains Solid in Fourth Quarter

    Commentary

    Fri, 31 Jan 2014

    CR Bard released solid fourth-quarter performance that generally matched our expectations, and we are leaving our fair value estimate

  9. Our Outlook for Health-Care Stocks

    Headlines

    Tue, 31 Dec 2013

    see China as a strategic priority and invested heavily to put down roots there. On the other hand, Edwards EW and C . R . Bard BCR have invested far less extensively in China and do not seem to view penetration of this market as a corporate priority

  10. CR Bard Reports Strong 3Q and We Plan to Raise our Fair Value Estimate

    Commentary

    Tue, 22 Oct 2013

    CR Bard posted strong third-quarter results that slightly exceeded our expectations. We plan to modestly raise our fair value estimate

« Prev1234Next »
Content Partners